ADA 2017

Glucose Control with Oral Insulin Tablet Similar to Injection in Study

By June 15, 2017

Fasting plasma glucose in the OI338GT group fell from 175mg/dL at baseline to 129mg/dL by end of treatment.

Obeticholic Acid Appears Beneficial for NASH Patients with T2DM

By June 14, 2017

Results showed that 57% of the OCA-treated group reached the primary endpoint of a ≥2-point improvement in NAFLD activity score (NAS) without worsening fibrosis, compared to 21% in the placebo group.

Alirocumab Shows Clinical Benefit in T2DM as Adjunct to Statin Therapy

By June 14, 2017

Praluent achieved its primary endpoint by decreasing LDL-C from baseline to Week 24 by 48.2%, compared to a 0.8% increase in the placebo arm.

Icosapent Ethyl Analyzed in Statin-Treated Women with T2D, High TG

By June 14, 2017

In the post-hoc analysis of a subgroup of statin-treated women with persistent high TG and type 2 diabetes (n=146), treatment with Vascepa 4g daily lowered TG, other atherogenic lipid markers, and inflammatory markers.

Ertugliflozin Evaluated as Add-On to Metformin, Sitagliptin

By June 14, 2017

The study found greater reductions in HbA1c among patients taking ertugliflozin 5mg or 15mg with metformin vs. placebo at 26 weeks (0.7% and 0.9% vs. 0.0%; P<0.001).

Switching to Toujeo Reduced Hypoglycemia Risk in Older Patients

By June 14, 2017

Study patients who switched to Toujeo were 57% less likely to have hypoglycemia at the 6-month follow-up (OR 0.432, 95% CI: 0.307-0.607; P<0.0001) vs. those who switched to another basal insulin.

Soliqua Beats Basal Insulin for HbA1c Reduction Regardless of Level at Screening

By June 13, 2017

After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively.

Similar A1C Reductions, Less Hypoglycemia with Xultophy Compared to Basal-Bolus Tx

By June 13, 2017

Compared to basal-bolus therapy, Xultophy 100/3.6-treated patients achieved A1c <7% with no hypoglycemia and no weight gain in the last 12 weeks.

Canagliflozin Significantly Reduces Cardiovascular Risks that Affect T2DM Patients

By June 13, 2017

Compared to placebo, canagliflozin reduced the risk of the composite primary endpoint (cardiovascular mortality, nonfatal MI, nonfatal stroke) by 14% (HR: 0.86; 95% CI: 0.75-0.97).

Cardiovascular Risks Examined for Degludec in T2D

June 13, 2017

The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5 and 9.3% of patients in the degludec and glargine groups, respectively.

Nasal Glucagon Evaluated for Hypoglycemia Management

June 13, 2017

In 96.2% of the episodes, blood glucose levels returned to normal within 30 minutes, the researchers found.

Glucose Self-Monitoring May Not Be Beneficial in T2DM, Says Landmark Study

By June 12, 2017

Results showed that by the end of the 1-year study, there were no significant differences in hemoglobin A1C levels or HRQOL across the three study arms.

Testosterone Therapy Benefits Men with Hypogonadism and T2D

June 11, 2017

At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.

SGLT2 Inhibitor May Protect Against Atherosclerosis in Type 2 Diabetes

June 11, 2017

Flow mediated dilation changes improved in patients who received dapagliflozin.

Sitagliptin Investigated in Prediabetic, Overweight Men

June 11, 2017

Sitagliptin improved glucose excursion and lowered triglyceride levels in men with prediabetes who were also overweight.

Liraglutide Beneficial for Antipsychotic-Induced Glucose Intolerance

June 10, 2017

Interventions seeking to counteract antipsychotic-induced weight gain and cardiometabolic disturbances have had limited success.